Variable-Sensitivity Force Sensor Based on Structural Modification.

Force sensors are used in a wide variety of fields. They require different measurement ranges and sensitivities depending on the operating environment because there is generally a trade-off between measurement range and sensitivity. In this study, we developed a variable-sensitivity, variable-measurement-range force sensor that utilizes structural modification, namely changes in the distance between the force application point and the detection area, and changes in the cross-sectional area. The use of shape-memory materials allows the sensor structure to be easily changed and fixed by controlling the temperature. First, we describe the theory of the proposed sensor. Then, we present prototypes and the experimental methods used to verify the performance of the sensor. We fabricated the prototypes by attaching two strain gauges to two sides of a shape-memory alloy and shape-memory polymer plates. Experiments on the prototypes show that the relationship between the applied force and the detected strain can be changed by bending the plate. This allows the sensitivity and measurement range of the sensor to be changed.

Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy.

Objective: The chronic kidney disease (CKD) is widely diagnosed on the basis of albuminuria and the glomerular filtration rate. A more precise diagnosis of CKD, however, requires the assessment of other factors. Urinary adiponectin recently attracted attention for CKD assessment, but evaluation is difficult due to the very low concentration of urinary adiponectin in normal subjects. Research design and methods: We developed an ultrasensitive ELISA coupled with thionicotinamide-adenine dinucleotide cycling to detect trace amounts of proteins, which allows us to measure urinary adiponectin at the subattomole level. We measured urinary adiponectin levels in 59 patients with diabetes mellitus (DM) and 24 subjects without DM (normal) to test our hypothesis that urinary adiponectin levels increase with progression of CKD due to DM. Results: The urinary adiponectin levels were 14.88±3.16 (ng/mg creatinine, mean±SEM) for patients with DM, and 3.06±0.33 (ng/mg creatinine) for normal subjects. The threshold between them was 4.0 ng/mg creatinine. The urinary adiponectin levels increased with an increase in the CKD risk. Furthermore, urinary adiponectin mainly formed a medium-molecular weight multimer (a hexamer) in patients with DM, whereas it formed only a low-molecular weight multimer (a trimer) in normal subjects. That is, the increase in urinary adiponectin in patients with DM led to the emergence of a medium-molecular weight form in urine. Conclusions: Our new assay showed that urinary adiponectin could be a new diagnostic index for CKD. This assay is a non-invasive test using only urine, thus reducing the patient burden.